OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing

References

• Cathcart MC, O'Byrne KJ, Reynolds JV, O'Sullivan J, Pidgeon GP. COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Biochim Biophys Acta 2011; 1825:49 - 63; PMID: 22015819
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA. Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin Oncol 2011; 38:533 - 541; PMID: 21810512; http://dx.doi.org/10.1053/j.seminoncol.2011.05.007
   PubMed Web of Science ®Google Scholar
• Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 2006; 15:713; PMID: 16328028
   PubMed Web of Science ®Google Scholar
• Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 2011; 12:1082 - 1093; PMID: 21443470; http://dx.doi.org/10.2174/138945011795677764
   PubMed Web of Science ®Google Scholar
• Moreira L, Castells A. Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention. Curr Drug Targets 2010; In press. PMID: 21158711
   PubMed Web of Science ®Google Scholar
• Cerella C, Sobolewski C, Dicato M, Diederich M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem Pharmacol 2010; 80:1801 - 1815; PMID: 20615394; http://dx.doi.org/10.1016/j.bcp.2010.06.050
   PubMed Web of Science ®Google Scholar
• Romagnolo DF, Papoutsis AJ, Selmin O. Nutritional targeting of cyclooxygenase-2 for colon cancer prevention. Inflamm Allergy Drug Targets 2010; 9:181 - 191; PMID: 20553228
   PubMedGoogle Scholar
• Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010; 62:233 - 244; PMID: 20508278
   PubMed Web of Science ®Google Scholar
• Patel MI, Subbaramaiah K, Du B, Chang M, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. (2005) Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005; 11:1999 - 2007; PMID: 15756026; http://dx.doi.org/10.1158/10780432.CCR-04-1877
   PubMed Web of Science ®Google Scholar
• Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS. Progress in COX-2 inhibitors: a journey so far. Curr Med Chem 2010; 17:1563 - 1593; PMID: 20166930; http://dx.doi.org/10.2174/092986710790979980
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang JW, Tseng PH, Yang YT, Fowble JW, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004; 64:4309 - 4318; PMID: 15205346; http://dx.doi.org/10.1158/0008-5472.CAN-03-4063
   PubMed Web of Science ®Google Scholar
• Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 2008; 73:1168 - 1184; PMID: 18182481; http://dx.doi.org/10.1124/mol.107.042697
   PubMed Web of Science ®Google Scholar
• Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006; 70:589 - 603; PMID: 16622074; http://dx.doi.org/10.1124/mol.106.025007
   PubMed Web of Science ®Google Scholar
• Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, et al. A novel celecoxib derivative, OSU-03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase-and Bcl-2-independent mechanism. Blood 2005; 105:2504 - 2509; PMID: 15454489; http://dx.doi.org/10.1182/blood-2004-05-1957
   PubMed Web of Science ®Google Scholar
• Tseng PH, Lin HP, Zhu J, Chen KF, Hade EM, Young DC, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 2005; 105:4021 - 4027; PMID: 15665113; http://dx.doi.org/10.1182/blood-2004-07
   PubMed Web of Science ®Google Scholar
• Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006; 70:1534 - 1541; PMID: 16887935; http://dx.doi.org/10.1124/mol.106.023911
   PubMed Web of Science ®Google Scholar
• To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, et al. The phosphoinositide-dependent kinase-1 inhibitor, OSU-03012, prevents Y-box binding protein-1 (YB-1) from inducing epidermal growth factor receptor (EGFR). Mol Pharmacol 2007; 72:641 - 652; PMID: 17595327; http://dx.doi.org/10.1124/mol.107.036111
   PubMed Web of Science ®Google Scholar
• Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434:181 - 188; PMID: 21309747; http://dx.doi.org/10.1042/BJ20101569
   PubMed Web of Science ®Google Scholar
• Bánhegyi G, Baumeister P, Benedetti A, Dong D, Fu Y, Lee AS, et al. Endoplasmic reticulum stress. Ann N Y Acad Sci 2007; 1113:58 - 71; PMID: 17483206; http://dx.doi.org/10.1196/annals.1391.007
   PubMed Web of Science ®Google Scholar
• McLaughlin M, Vandenbroeck K. The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?. Br J Pharmacol 2011; 162:328 - 345; PMID: 20942857; http://dx.doi.org/10.1111/j.1476-5381.2010.01064.x
   PubMed Web of Science ®Google Scholar
• Ishihara T, Tanaka K, Tashiro S, Yoshida K, Mizushima T. Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. Biochem Pharmacol 2010; 79:1622 - 1633; PMID: 20132796; http://dx.doi.org/10.1016/j.bcp.2010.01.030
   PubMed Web of Science ®Google Scholar
• Ye J, Koumenis C. ATF4, an ER stress and hypoxiainducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis. Curr Mol Med 2009; 9:411 - 416; PMID: 19519398; http://dx.doi.org/10.2174/156652409788167096
   PubMed Web of Science ®Google Scholar
• Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7:1013 - 1030; PMID: 19043451; http://dx.doi.org/10.1038/nrd2755
   PubMed Web of Science ®Google Scholar
• Sjöström J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmström P, et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002; 8:811 - 816; PMID: 11895913
   PubMed Web of Science ®Google Scholar
• Diehl JA, Fuchs SY, Koumenis C. The cell biology of the unfolded protein response. Gastroenterology 2011; 141:38 - 41; PMID: 21620842; http://dx.doi.org/10.1053/j.gastro.2011.05.018
   PubMed Web of Science ®Google Scholar
• Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, et al. PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 2010; 29:3881 - 3895; PMID: 20453876; http://dx.doi.org/10.1038/onc.2010.153
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Chen AW, Varner JD. A review of the mammalian unfolded protein response. Biotechnol Bioeng 2011; 108:2777 - 2793; PMID: 21809331; http://dx.doi.org/10.1002/bit.23282
   PubMed Web of Science ®Google Scholar
• de Ridder G, Ray R, Misra UK, Pizzo SV. Modulation of the unfolded protein response by GRP78 in prostate cancer. Methods Enzymol 2011; 489:245 - 257; PMID: 21266234; http://dx.doi.org/10.1016/B978-012-385116-1.00014-5
   PubMed Web of Science ®Google Scholar
• Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011; 101:57 - 66; PMID: 20443129; http://dx.doi.org/10.1007/s11060-010-0217-6
   PubMed Web of Science ®Google Scholar
• Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S, et al. Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol 2010; 32:511 - 514; PMID: 20463608; http://dx.doi.org/10.1097/MPH.0b013e3181d74702
   PubMed Web of Science ®Google Scholar